SGTX
Price:
$22.47
Market Cap:
$56.22M
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has ...[Read more]
Industry
Biotechnology
IPO Date
2020-12-04
Stock Exchange
NASDAQ
Ticker
SGTX
According to Sigilon Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -1.52. This represents a change of -77.93% compared to the average of -6.86 of the last 4 quarters.
The mean historical PE Ratio of Sigilon Therapeutics, Inc. over the last ten years is -14.49. The current -1.52 PE Ratio has changed 945.32% with respect to the historical average. Over the past ten years (40 quarters), SGTX's PE Ratio was at its highest in in the December 2019 quarter at 0. The PE Ratio was at its lowest in in the December 2020 quarter at -135.97.
Average
-14.49
Median
-16.42
Minimum
-27.54
Maximum
-1.12
Discovering the peaks and valleys of Sigilon Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 201.88%
Maximum Annual PE Ratio = -1.12
Minimum Annual Increase = -95.92%
Minimum Annual PE Ratio = -27.54
Year | PE Ratio | Change |
---|---|---|
2022 | -3.39 | 201.88% |
2021 | -1.12 | -95.92% |
2020 | -27.54 | 67.74% |
2019 | -16.42 | -31.55% |
The current PE Ratio of Sigilon Therapeutics, Inc. (SGTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-10.69
5-year avg
-14.49
10-year avg
-14.49
Sigilon Therapeutics, Inc.’s PE Ratio is less than Reviva Pharmaceuticals Holdings, Inc. (-1.10), less than ZyVersa Therapeutics, Inc. (-0.10), less than Kiromic BioPharma, Inc. (-0.14), less than Unicycive Therapeutics, Inc. (-0.46), less than Oncorus, Inc. (-0.04), less than eFFECTOR Therapeutics, Inc. (-0.00), less than Apollomics, Inc. (-0.22), less than Angion Biomedica Corp. (-0.24), less than Cardio Diagnostics Holdings, Inc. (-0.75), less than Sonnet BioTherapeutics Holdings, Inc. (-0.55), less than X4 Pharmaceuticals, Inc. (7.41), greater than Landos Biopharma, Inc. (-5.74), less than Apexigen, Inc. (-0.36), less than Navidea Biopharmaceuticals, Inc. (0.03), less than NovaBay Pharmaceuticals, Inc. (-0.05), less than InMed Pharmaceuticals Inc. (-0.42), less than GeoVax Labs, Inc. (-0.32), less than Phio Pharmaceuticals Corp. (-0.15),
Company | PE Ratio | Market cap |
---|---|---|
-1.10 | $44.68M | |
-0.10 | $2.70M | |
-0.14 | $3.14M | |
-0.46 | $33.41M | |
-0.04 | $3.14M | |
-0.00 | $188.18K | |
-0.22 | $14.97M | |
-0.24 | $30.11M | |
-0.75 | $6.94M | |
-0.55 | $4.53M | |
7.41 | $109.78M | |
-5.74 | $71.68M | |
-0.36 | $9.57M | |
0.03 | $100.08K | |
-0.05 | $2.18M | |
-0.42 | $2.38M | |
-0.32 | $28.68M | |
-0.15 | $2.25M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Sigilon Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Sigilon Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Sigilon Therapeutics, Inc.'s PE Ratio?
How is the PE Ratio calculated for Sigilon Therapeutics, Inc. (SGTX)?
What is the highest PE Ratio for Sigilon Therapeutics, Inc. (SGTX)?
What is the 3-year average PE Ratio for Sigilon Therapeutics, Inc. (SGTX)?
What is the 5-year average PE Ratio for Sigilon Therapeutics, Inc. (SGTX)?
How does the current PE Ratio for Sigilon Therapeutics, Inc. (SGTX) compare to its historical average?